CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. Our lead drug, Berubicin, is an exciting discovery for the treatment of Glioblastoma Multiforme (GBM) and potentially for other CNS malignancies. Berubicin was first discovered at the MD Anderson Cancer Center, one of the largest cancer institutes in the world. CNS has obtained a worldwide exclusive license to the Berubicin patent from Houston Pharmaceuticals, the original commercial holder of the Berubicin intellectual property. CNS has also acquired all data and know-how related to the Phase 1 trial of Berubicin from Reata Pharmaceuticals, a multibillion dollar NASDAQ listed company. In 2017, CNS entered into a collaboration agreement with Reata to further advance the development of Berubicin. In 2019, with the funding secured from our NASDAQ IPO, CNS will commence its Phase 2(a) clinical trial of Berubicin for the treatment of GBM. CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.
No articles found.
Robovet Corporation has developed a new MR imaging technology that can also help t...
Robovet Corporation has developed a new MR imag...
Insulet Corporation is an innovative medical device company based in Acton, Massac...
Insulet Corporation is an innovative medical de...
STRATA Skin Sciences is a medical technology company focused on the therapeutic an...
STRATA Skin Sciences is a medical technology co...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
For more than 40 years, Option Care has been shaping the home infusion services in...
For more than 40 years, Option Care has been sh...
Join the National Investor Network and get the latest information with your interests in mind.